Apr 22, 2020
Genetic Cancer Patients Report COVID-19 Crisis Impacts Medical Care
Mar 09, 2020
Lutetium-177 Market & Pipeline Outlook, 2026: GEP-NET & Prostate Cancer Market Indications, Lu-177 Therapy Market Size, Eligible Patients Pool, Opportunity & Demand for Lu-177 Isotope
Jan 30, 2020
Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill(TM)
Jan 07, 2020
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)
Dec 12, 2019
Global Somatostatin Analogs Industry Outlook, 2019-2026 - Pasireotide Estimated to Be the Fastest Growing Segment Over the Forecast Period
Nov 07, 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
Nov 07, 2019
Global Neuroendocrine Tumors (NETs) Market Report 2019
Oct 07, 2019
Nordic Nanovector Signs Global Clinical and Commercial Agreement With ITM for the Supply of No-carrier-added Lutetium-177
Jun 20, 2019
Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Jun 11, 2019
Neuroendocrine Tumor Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jun 03, 2019
NET (Neuroendocrine Tumor) Treatment Market Size Worth $3.33 Billion By 2025 | CAGR 10.4%: Grand View Research, Inc.
Dec 12, 2018
Entrinsic Health Solutions and Markey Cancer Center Launch Phase II Study for Neuroendocrine Tumor Patients with Quality of Life-Limiting Diarrhea
Oct 16, 2018
Health Canada approves XERMELO(TM) (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)
Oct 09, 2018
Navigating Neuroendocrine Tumors
Sep 20, 2018
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
Sep 17, 2018
Global Pancreatic Fistula Treatment Market to 2026 - Aggressive Diagnosis and Minimally Invasive Procedures Presents Market Opportunities
Jul 12, 2018
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
Feb 22, 2018
Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
Feb 15, 2018
Global Neuroendocrine Tumors (NET) Market Report 2017: Novartis Leads Industry Sponsors with the Highest Number of Clinical Trials for NETs, Followed by Ipsen and Pfizer
Feb 13, 2018
Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)